Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET-743 (Yondelis) in Advanced Soft Tissue Sarcoma
NCT00017030Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2001
- Primary completion
- Jan 2003
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trabectedin in soft tissue sarcoma (STS) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Clinical Benefit Rate. Started Feb 2001; status: completed.
02
Drugs
trabectedin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT00017030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00017030.